MannKind’s Future Uncertain After Sanofi Terminates Afrezza Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
During a very brief investor call, MannKind says it is planning to change its pricing and contracting tactics, after being left in the lurch as Sanofi terminates its development and commercialization deal on the inhaled insulin Afrezza.